A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

  • Eye Disorder
  • Choroidal neovascularization
  • Myopia
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • bei-jing-shi
  • Beijing
  • Bydgoszcz
  • chang-chun-shi
  • Chieti
  • Créteil
  • czelad_
  • Córdoba
  • Daegu
  • East Melbourne
  • Freiburg im Breisgau
  • guang-zhou-shi
  • Göttingen
  • Harbin
  • Hong Kong Island
  • Kraków
  • Köln
  • Liverpool
  • Lublin
  • Lyon
  • Madrid
  • Marseille
  • Milano
  • München
  • Münster
  • New Taipei City
  • Olsztyn
  • Pamplona
  • Paris
  • Qingdao
  • Roma
  • Rowville
  • Saint-Cyr-sur-Loire
  • Seoul
  • shang-hai-shi
  • Shanghai
  • Shenyang
  • Singapore
  • Strathfield
  • sulzbach-saar
  • Sydney
  • tai-yuan-shi
  • Taipei City
  • tian-jin-shi
  • Toronto
  • wen-zhou-shi
  • wu-xi-shi
  • Wuhan
  • Xi'an
Trial Identifier:

NCT06176352 2023-506707-25-00 CR44829

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT06176352,CR44829,2023-506707-25-00 Trial Identifier
      Faricimab, Ranibizumab, Sham Procedure Treatments
      Choroidal Neovascularization Secondary to Pathologic Myopia Condition
      Official Title

      A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Treatment-naïve choroidal neovascularization (CNV) secondary to myopia
      • Diagnosis of active myopic CNV in the study eye:
      • Presence of high myopia, worse than -6 diopters of spherical equivalence 2. Antero-posterior elongation measurement greater than or equal to 26.0 mm 3. Presence of posterior changes compatible with pathologic myopia (e.g., tessellated fundus, lacquer cracks, etc.) 4. Presence of active leakage from CNV on FFA (determined by Central Reading Centre [CRC]) 5. Presence of intraretinal or subretinal fluid or increase of CST on OCT (determined by CRC)
      • BCVA of 78 to 24 letters, inclusive (20/32 to 20/320 approximate Snellen equivalent), using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol on Day 1
      • Overtly healthy as determined by medical evaluation that includes medical history, physical examination, and laboratory tests
      • Ability to comply with the study protocol, in the Investigator's judgment
      • Other protocol-defined inclusion criteria apply
      Exclusion Criteria
      • Any major illness or major surgical procedure within 1 month before screening
      • Pregnancy or breastfeeding, or intention to become pregnant during the study or within 3 months after the final study treatment administration
      • Uncontrolled blood pressure (systolic >180 millimetres of mercury [mmHg], diastolic >100 mmHg)
      • Stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to Day 1
      • History of systemic or ocular disease that would contraindicate treatment with the investigational drug or comparator
      • Uncontrolled glaucoma in study eye
      • Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities, including, but not restricted to, intravitreal, periocular or laser interventions in study eye
      • Prior or concomitant periocular or intravitreal pharmacological treatment, including anti-VEGF medication, for other retinal diseases (e.g. geography atrophy, nAMD, DME etc.) in study eye
      • Other protocol-defined exclusion criteria apply

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now